Second Annual Immuno-Oncology Symposium November 4 in Moncton
(MONCTON) - The new era of immunotherapy and its role in the successful treatment of lung cancer, melanoma and other cancers will be the focus of the Second Annual Immono-Oncology Symposium in Moncton on November 4, 2016.
Chaired by Dr. Mahmoud Abdelsalam, oncologist with Horizon Health Network, the symposium will be held at the Four Points Sheraton from 9 a.m. to 3 p.m.
"This very important symposium brings together experts in the field of immunotherapy and malignancies," said Dr. Édouard Hendriks, Vice-president, Medical, Academic and Research Affairs, with Horizon Health Network. "We'll be advancing knowledge and the education of our specialists, family practice and emergency physicians, nurses and pharmacists."
The scientific committee hosting the event is comprised of medical oncologists from both The Moncton Hospital and the Dr. Georges-L.-Dumont University Hospital Centre, in addition to clinical pharmacists from The Moncton Hospital.
Over 100 clinicians are expected to attend the symposium including medical and radiology oncologists, GPOs, oncology nurses, radiation therapists, pharmacists and medical laboratory technicians.
"Immunotherapy has its own unique side effects that vary from those of chemotherapy," Dr. Abdelsalam said. "Managing treatment and side effects is completely different from the approach used with other anti-cancer drugs underscoring the relevance of our impressive lineup of presentations."
Dr. Wilson Miller, the James McGill professor in the departments of oncology and medicine at McGill University, will deliver the keynote address titled Immunotherapy beyond Checkpoint and Future Directions in IT and Melanoma Highlights.
Other speakers will include Dr. John Kuruvilla, Princess Margaret Cancer Centre, Toronto, addressing the subject of immunotherapy in hematologic malignancies and future prospects; Dr. Arik Drucker, Nova Scotia Cancer Centre, speaking about immunotherapy in lung cancer; and Dr. Francisco Emilio Vera-Badillo, of the Canadian Cancer Trials Group, discussing genito-urinary cancer immunotherapy and future directions.